![Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial - The Lancet Respiratory Medicine Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/9cb9538a-d12c-449e-a2ac-2782736af3f9/gr2_lrg.jpg)
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial - The Lancet Respiratory Medicine
![Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial - The Lancet Rheumatology Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/4d12200d-a2cb-40f4-b1f0-6dcd6d192d8c/gr1_lrg.gif)
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial - The Lancet Rheumatology
![Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials - ScienceDirect Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1567576922002703-ga1.jpg)